In the six decades since Watson and Crick discovered the structure of DNA, rarely has a year passed in the biopharmaceutical sector which could be defined as boring. The scientific revelations continue to yield intellectual property for businesses to develop. And investors scramble to identify and back potential blockbuster targets. Read More
By integrating fragments of target proteins into the antibodies that bind to them, researchers have been able to take up to 10 amyloid proteins per antibody out of commission, preventing them from forming toxic amyloid fibrils. Read More
John Steel is running for his life. Diagnosed with Type I diabetes 30 years ago, the president and CEO of Islet Sciences Inc. endures a daily regimen of insulin injections and glucose monitoring. Read More
• NanoViricides Inc., of West Haven, Conn., received the final tranche of $2.5 million from Seaside 88 LP, thereby completing the total of a $5 million financing disclosed in June. Read More
• GeneNews Ltd., of Toronto, posted its common shares for trading on Dec. 24, on a 1-for-6 consolidated basis. That resulted in 33,744,883 issued and outstanding shares. Any fractional shares will be rounded up or down to the nearest round number. Read More
• Celator Pharmaceuticals Inc., of Princeton, N.J., treated its first patient in a Phase III, randomized, open-label trial of CPX-351 (cytarabine/daunorubicin) liposome injection compared to conventional cytarabine and daunorubicin for first-line therapy of acute myeloid leukemia. Read More
• The European Medicines Agency accepted submission of a marketing authorization application for aripiprazole depot formulation by Otsuka Pharmaceutical Co. Ltd., of Tokyo, and H. Lundbeck A/S, of Copenhagen. The application is for once-monthly injection for maintenance treatment of adults with schizophrenia. It is designed for relapse prevention. Read More
